← back to search

Lei Jin

University Hospital Münster · DE
Area of research
Molecular Biology · Cancer Research
Research interest
Research interests include Cancer-related gene regulation, Biochemical and Molecular Research, Epigenetics and DNA Methylation, and Cancer, Hypoxia, and Metabolism.
h-index
40
citations
10,209
works
86
NIH funding
primary concept
email

Recent publications

Structure-Based Design of AG-946, a Pyruvate Kinase Activator.
2024cited by 7position: contributordoi
Supplementary Data Table S4 from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
2023cited by 0position: contributordoi
Supplementary Data from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
2023cited by 0position: contributordoi
Supplementary Data Table S3 from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
2023cited by 0position: contributordoi
Supplementary Data from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
2023cited by 0position: contributordoi
Supplementary Data Table S2 from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
2023cited by 0position: contributordoi
Supplementary Data Table S3 from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
2023cited by 0position: contributordoi
Supplementary Data Table S2 from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
2023cited by 0position: contributordoi
Data from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
2023cited by 0position: contributordoi
Data from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
2023cited by 0position: contributordoi
Supplementary Data Table S1 from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
2023cited by 0position: contributordoi
Supplementary Data Table S4 from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
2023cited by 0position: contributordoi
Supplementary Data Table S1 from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
2023cited by 0position: contributordoi
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase.
2020cited by 29position: contributordoi
Small-Molecule Positive Allosteric Modulators of the β2-Adrenoceptor Isolated from DNA-Encoded Libraries
Molecular Pharmacology 2018cited by 92position: middledoi
Structure of a Bimodular Botulinum Neurotoxin Complex Provides Insights into Its Oral Toxicity
PLoS Pathogens 2013cited by 124position: middledoi
3.5Å cryoEM Structure of Hepatitis B Virus Core Assembled from Full-Length Core Protein
PLoS ONE 2013cited by 111position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Anil K. Padyana · Biogen (United States)14 papers (2020–2024) · 14 papers (2020–2024)Kevin Truskowski · Johns Hopkins University13 papers (2020–2023) · 1 papers (2013–2013) · 1 papers (2013–2013)Thomas Franch · Amgen (United States)1 papers (2018–2018)Thomas T. Xu · Ragon Institute of MGH, MIT and Harvard1 papers (2018–2018)Anna Magdalena Kruel · Medizinische Hochschule Hannover1 papers (2013–2013) · 1 papers (2024–2024) · 1 papers (2024–2024)Lenny Dang · Agios Pharmaceuticals (United States)1 papers (2024–2024)Paula Rambarat · Duke University Health System1 papers (2018–2018)Guorui Yao · Xiamen University1 papers (2013–2013)Shuai Zhao · Anhui Normal University1 papers (2018–2018)Li-Yin Huang · Duke Medical Center1 papers (2018–2018)Chiaho Shih · National Taiwan University1 papers (2013–2013)Paul J. Shim · Beth Israel Deaconess Medical Center1 papers (2018–2018)Jonathan Jih · University of California, Los Angeles1 papers (2013–2013)Eva K. Olsen · Changzhou University1 papers (2018–2018)M. Vestergaard · University of Copenhagen1 papers (2018–2018)